CY1105189T1 - Χρηση συνδυασμου που πepιεχει 4-πυριδυλομεθυλοφθαλαζινες για τη θepαπεια του καρκινου - Google Patents

Χρηση συνδυασμου που πepιεχει 4-πυριδυλομεθυλοφθαλαζινες για τη θepαπεια του καρκινου

Info

Publication number
CY1105189T1
CY1105189T1 CY20061101239T CY061101239T CY1105189T1 CY 1105189 T1 CY1105189 T1 CY 1105189T1 CY 20061101239 T CY20061101239 T CY 20061101239T CY 061101239 T CY061101239 T CY 061101239T CY 1105189 T1 CY1105189 T1 CY 1105189T1
Authority
CY
Cyprus
Prior art keywords
cancer
pyridylmethylphthalazines
treatment
combination containing
phthalazine
Prior art date
Application number
CY20061101239T
Other languages
English (en)
Inventor
Margaret Han Dugan
Jeanette Marjorie Wood
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1105189T1 publication Critical patent/CY1105189T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Ασθενείς που υποφέρουν από νεφρικό καρκίνωμα υφίστανται θεραπεία με μια αντι-αγγειογονική ουσία 4-πυριδυλομεθυλο-φθαλαζίνη. Ασθενείς που εμφανίζουν διάφορα είδη όγκων, π.χ. νεφρικός καρκίνος, υφίστανται θεραπεία με αντι-αγγειογονική ουσία 4-πυριδυλομεθυλο-φθαλαζίνη ενώ υφίστανται χημειοθεραπεία.
CY20061101239T 2001-09-12 2006-08-31 Χρηση συνδυασμου που πepιεχει 4-πυριδυλομεθυλοφθαλαζινες για τη θepαπεια του καρκινου CY1105189T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US33102501P 2001-09-12 2001-09-12
US31869401P 2001-09-12 2001-09-12
US32204401P 2001-09-14 2001-09-14
US38816302P 2002-06-12 2002-06-12
PCT/EP2002/010194 WO2003022282A1 (en) 2001-09-12 2002-09-11 Use of 4-pyridylmethylphthalazines for cancer treatment

Publications (1)

Publication Number Publication Date
CY1105189T1 true CY1105189T1 (el) 2010-03-03

Family

ID=27502161

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101239T CY1105189T1 (el) 2001-09-12 2006-08-31 Χρηση συνδυασμου που πepιεχει 4-πυριδυλομεθυλοφθαλαζινες για τη θepαπεια του καρκινου

Country Status (22)

Country Link
US (2) US20040258770A1 (el)
EP (1) EP1427420B1 (el)
JP (1) JP2005502690A (el)
KR (1) KR20040029172A (el)
CN (1) CN1330308C (el)
AT (2) ATE329597T1 (el)
AU (2) AU2002342678B2 (el)
BR (1) BR0212446A (el)
CA (1) CA2457848A1 (el)
CO (1) CO5560545A2 (el)
CY (1) CY1105189T1 (el)
DE (2) DE60231068D1 (el)
DK (1) DK1427420T3 (el)
ES (2) ES2320922T3 (el)
HR (1) HRP20040241A2 (el)
IL (1) IL160382A0 (el)
NO (1) NO327358B1 (el)
NZ (1) NZ531484A (el)
PL (1) PL367349A1 (el)
PT (1) PT1427420E (el)
RS (1) RS16804A (el)
WO (1) WO2003022282A1 (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0223341D0 (en) * 2002-10-08 2002-11-13 Groningen Acad Ziekenhuis Organic compounds
EP1738752A1 (en) * 2002-12-27 2007-01-03 Schering Aktiengesellschaft Pharmaceutical combinations comprising cis-retine acid
WO2004105747A1 (en) * 2003-05-20 2004-12-09 Aronex Pharmaceuticals, Inc Combination chemotherapy comprising capecitabine and a liposomal platinum complex
JP2007505938A (ja) * 2003-09-23 2007-03-15 ノバルティス アクチエンゲゼルシャフト Ｖｅｇｆ受容体阻害剤と化学療法剤の組み合わせ
GB0610925D0 (en) * 2006-06-02 2006-07-12 Novartis Ag Use of vascular endothelial growth factor receptor inhibitors for the treatment of cancer
KR101037292B1 (ko) * 2010-09-03 2011-05-27 (주)슈추어 신발 장식구

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849741A (en) * 1994-08-09 1998-12-15 Eisai Co., Ltd. Fused pyridazine compounds
NZ331191A (en) * 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
US6096904A (en) * 1996-12-03 2000-08-01 The Trustees Of The University Of Pennsylvania Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion

Also Published As

Publication number Publication date
US20040258770A1 (en) 2004-12-23
DE60212415T2 (de) 2006-11-23
PL367349A1 (en) 2005-02-21
ES2320922T3 (es) 2009-05-29
JP2005502690A (ja) 2005-01-27
NO327358B1 (no) 2009-06-15
BR0212446A (pt) 2004-08-17
KR20040029172A (ko) 2004-04-03
WO2003022282A1 (en) 2003-03-20
RS16804A (en) 2007-02-05
DE60212415D1 (de) 2006-07-27
CN1553803A (zh) 2004-12-08
AU2002342678B2 (en) 2006-08-24
US20090196871A1 (en) 2009-08-06
ATE421880T1 (de) 2009-02-15
EP1427420B1 (en) 2006-06-14
CN1330308C (zh) 2007-08-08
ES2266590T3 (es) 2007-03-01
ATE329597T1 (de) 2006-07-15
EP1427420A1 (en) 2004-06-16
NO20040973L (no) 2004-06-03
AU2006203428A1 (en) 2006-08-31
CO5560545A2 (es) 2005-09-30
DK1427420T3 (da) 2006-10-02
DE60231068D1 (de) 2009-03-19
CA2457848A1 (en) 2003-03-20
IL160382A0 (en) 2004-07-25
PT1427420E (pt) 2006-10-31
HRP20040241A2 (en) 2005-04-30
AU2006203428B2 (en) 2009-06-04
NZ531484A (en) 2007-02-23

Similar Documents

Publication Publication Date Title
CY1119029T1 (el) Θεραπευτικη αντιμετωπιση συμπαγων εγκεφαλικων νεοπλασιων με ενα παραγωγο ραπαμυκινης
CY1105189T1 (el) Χρηση συνδυασμου που πepιεχει 4-πυριδυλομεθυλοφθαλαζινες για τη θepαπεια του καρκινου
EA200100111A1 (ru) Ингибиторы фарнезилпротеинтрансферазы, обладающие in vivo радиосенсибилизирующими свойствами
CY1114159T1 (el) K-ras και b-raf μεταλλαξεις και αντι-egfr θεραπεια με αντισωματα
PT1315520E (pt) Utilizacao de anticorpos trifuncionais biespecificos e triespecificos para tratamento de ascites malignas
CY1112458T1 (el) Ενα αντισωμα ειδικο για διαλυτο baff για χρηση στην αντιμετωπιση του καρκινου
BR9908823A (pt) Compostos e processos para terapia e diagnóstico de câncer de pulmão
CY1105191T1 (el) Συνδετες διττης εξειδικευσης με αυξημενη ημιζωη ορου
DK1119371T3 (da) Flt4 (VEGFR-3) som et mål for tumorbilleddannelse og antitumorterapi
CY1113637T1 (el) Ενωση αμινο πυραζολης
AR033157A1 (es) Uso de proteina alfa de activacion de los fibroblastos ("fapaalfa")bibh1 en el tratamiento del cancer
EA200400235A1 (ru) Комбинированная терапия для лечения рака
WO2003079020A3 (en) Methods and compositions for the identification, assessment, and therapy of small cell lung cancer
WO2006060819A3 (en) Dhmeq as a sensitizing agent for chemotherapy and immunotherapy of resistant cancer cells
WO2003093794A3 (en) Methods for discovering tumor biomarkers and diagnosing tumors
ATE435647T1 (de) Rutheniumkomplexe zur krebsbehandlung
ATE371664T1 (de) Proteinbindende derivate von platinkomplexen mit cyclobutan-1,1-dicarboxylatliganden
ECSP044991A (es) Uso de 4-piridilmetil-ftalazinas para el tratamiento de cancer
DK1154798T3 (da) Molekyler til behandling og diagnose af tumorer
MXPA04002407A (es) Uso de 4-piridilmeetil-ftalazinas para el tratamiento de cancer.
AU2001256440A1 (en) Medicines for treating tumoral pathologies containing the ro5-4864 compound and an apoptosis-inducing agent
PL1819354T3 (pl) Sposoby i związki do leczenia cukrzycy
ATE520031T1 (de) Ibc-1 (invasive breast cancer-1), ein bei brustkrebs amplifiziertes mutmassliches onkogen
WO2005046607A3 (en) Combinations for the treatment of proliferative diseases
CY1115659T1 (el) Μεσα ειδικης δεσμευσης στον αυξητικο παραγοντα των ηπατοκυτταρων